The risk of medication-free research

Schizophrenia Bulletin

Volumn 23, Issue 1, 1997, Pages 11-18

  Carpenter Jr , William T ^a,b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0343118718     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/23.1.11     Document Type: Article

References (93)

1. Angst, J. European long-term followup studies of schizophrenia. Schizophrenia Bulletin, 14(4):501-513, 1988.
2. Angst, J.; Scharfetter, C.; and Strassen, H.H. Syndromwechsel und Remission schizophrener Psychosen. In: Huber, G., ed. Schizophrenie - Stand und Entwicklungstendenzen der Forschung. Vol. 4. Stuttgart, Germany: Schattauer, 1981. pp. 117-133.
3. Asarnow, J.R. Children at risk for schizophrenia: Converging lines of evidence. Schizophrenia Bulletin, 14(4):613-631, 1988.
4. Astrup, C., and Noreik, K. Functional Psychoses: Diagnostic and Prognostic Models. Springfield, IL: Charles C Thomas, 1966.
5. Bartels, S.J., and Drake, R.E. Depressive symptoms in schizophrenia: Comprehensive differential diagnosis. Comprehensive Psychiatry, 29(5):467-483, 1988.
6. Benes, F.M.; Paskevich, P.A.; and Domesick, V.B. Haloperidol-induced plasticity of axon terminals in rat substantia nigra. Science, 221:969-971, 1983.
7. Bleuler, M. The Schizophrenic Disorders: Long-Term Patient and Family Studies. Translated by S. H. Clemens. New Haven, CT: Yale University Press, 1978.
8. Bockoven, J.S., and Solomon, H.C. Comparison of two five-year follow-up studies: 1947 to 1952 and 1967 to 1972. American Journal of Psychiatry, 132:796-801, 1975.
9. Bremner, J.D.; Randall, P.; Scott, T.M.; Bronen, R.A.; Seibyl, J.P.; Southwick, S.M.; Delaney, R.C.; McCarthy, G.; Charney, D.S.; and Innis, R.B. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. American Journal of Psychiatry, 152:973-981, 1995.
10. Buchanan, R.W.; Holstein, C.; and Breier, A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry; 36:717-725, 1994.
11. Cardon, P.V.; Dommel, F.W.; and Trumble, R.R. Injuries to research subjects: A survey of investigators. New England Journal of Medicine, 295:650-654, 1976.
12. Carpenter, W.T., Jr.; Hanlon, T.E.; Heinrichs, D.W.; Summerfelt, A.T.; Kirkpatrick, B.; Levine, J.; and Buchanan, R.W. Continuous versus targeted medication in schizophrenic outpatients: Outcome results. American Journal of Psychiatry, 147:1138-1148, 1990.
13. Carpenter, W.T., Jr., and Heinrichs, D.W. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophrenia Bulletin, 9(4):533-542, 1983.
14. Carpenter, W.T., Jr.; Heinrichs, D.W.; and Hanlon, T.E. A comparative trial of pharmacologic strategies in schizophrenia. American Journal of Psychiatry, 144:1466-1470, 1987.
15. Carpenter, W.T., Jr.; Schooler, N.R.; and Kane, J.M. The ethics and deemed necessity of medication-free research in schizophrenia. Archives of General Psychiatry, in press.
16. Carroll, R.S.; Miller, A.; Ross, B.; and Simpson, G.M. Research as an impetus to improved treatment. Archives of General Psychiatry, 37:377-380, 1980.
17. Coplan, J.D.; Andrews, M.W.; Rosenblum, L.A.; Owens, M.J.; Friedman, S.; Gorman, J.M.; and Nemeroff, C.B. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult non-human primates exposed to early life stressors: Implications for the pathophysiology of mood and anxiety disorders. Proceedings of the National Academy of Sciences of the United States of America, 93(4):1619-1623, 1996.
18. Crow, T.J.; Macmillan, J.F.; Johnson, A.L.; and Johnstone, E.C. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148:120-127, 1986.
19. Curson, D.A.; Hirsch, S.R.; Platt, S.D.; Bamber, R.W.; and Barnes, T.R.E. Does short-term placebo treatment of chronic schizophrenia produce long-term harm? British Medical Journal, 293:726-728, 1986.
20. Falloon, I.R.H. Early intervention for episodes of schizophrenia: A preliminary exploration. Psychiatry, 55:4-15, 1992.
21. Galdi, J. The causality of depression in schizophrenia. British Journal of Psychiatry, 142:621-624, 1983.
22. Gariano, R.F.; Young, S.J.; Jeste, D.V.; Segal, D.S.; and Groves, P.M. Effects of long-term administration of haloperidol on electrophysiologic properties of rat mesencephalic neurons. Journal of Pharmacology and Experimental Therapeutics, 255:108-113, 1990.
23. Giller, E., and Strauss, J. Clinical research: A key to clinical training. American Journal of Psychiatry, 141:1075-1077, 1984.
24. Goldberg, T.E.; Greenberg, R.D.; Griffin, S.J.; Gold, J.M.; Kleinman, J.E.; Pickar, D.; Schulz, S.C.; and Weinberger, D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162:43-48, 1993.
25. Häfner, H., and Maurer, K. Epidemiology of positive and negative symptoms in schizophrenia. In: Shriqui, C.L., and Nasrallah, H.A., eds. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press, 1995. pp. 125-154.
26. Häfner, H., and Nowotny, B. Epidemiology of early-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 245:80-92, 1995.
27. Hagger, C.; Buckley, P.; Kenney, J.T.; Friedman, L.; Ubogy, D.; and Meltzer, H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34:702-712, 1993.
28. Hawk, A.B.; Carpenter, W.T., Jr.; and Strauss, J.S. Diagnostic criteria and 5-year outcome in schizophrenia: A report from the International Pilot Study of Schizophrenia. Archives of General Psychiatry, 32:343-356, 1975.
29. Herz, M.I.; Glazer, W.M.; Mostert, M.A.; Sheard, M.A.; Szymanski, H.V.; Hafez, H.; Mirza, M.; and Vana, J. Intermittent vs. maintenance medication in schizophrenia: Two-year results. Archives of General Psychiatry, 48:333-339, 1991.
30. Hilts, P.J. Agency faults a U.C.L.A. study for suffering of mental patients. The New York Times, March 10, 1994a. pp. A1, A11.
31. Hilts, P.J. Medical experts testify on tests done without consent. The New York Times, May 24, 1994b. "National" section.
32. Huber, G.; Gross, G.; and Schüttler, R. Schizophrenie, Verlaufs-und soczialpsychiatrische Langzeituntersuchungen an den 1945 bis 1959 in Bonn hospitalisierten schizophrenen Kranken. Berlin, Germany: Springer-Verlag, 1979.
33. Huber, G.; Gross, G.; and Schüttler, R. Longitudinal studies of schizophrenic patients. Translated by S.M. Clemens. Schizophrenia Bulletin, 6(4):592-605, 1980.
34. Jensen, T.S.; Genefke, I.K.; Hyldebrandt, N.; Pedersen, H.; Petersen, H.D.; and Weile, B. Cerebral atrophy in young torture victims. [Letter] New England Journal of Medicine, 307(21): 1341, 1982.
35. Jeste, D.V.; Lohr, J.B.; and Manley, M. Study of neuropathologic changes in the striatum following 4, 8, and 12 months of treatment with fluphenazine in rats. Psychopharmacology, 106:154-160, 1992.
36. Johnstone, E.C.; Macmillan, J.F.; Frith, C.D.; Benn, D.K.; and Crow, T.J. Further investigation of the predictors of outcome following first schizophrenic episodes. British Journal of Psychiatry, 157:182-189, 1990.
37. Jolley, A.G.; Hirsch, S.R.; McRink, A.; and Manchanda, R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical outcome at one year. British Medical Journal, 298:985-990, 1989.
38. Jolley, A.G.; Hirsch, S.R.; and Morrison, E. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. British Medical Journal, 301:837-842, 1990.
39. Kalman, T.P.; Talon, N.S.; Frances, A.; and Kocsis, J.H. A controlled study of satisfaction among psychobiology research patients. American Journal of Psychiatry, 139:344-347, 1982.
40. Katz, J. Human experimentation and human rights. Saint Louis University Law Journal, 38:7-54, 1993.
41. Kellner, C.H.; Roy-Byrne, P.P.; Rubinow, D.R.; Gold, P.W.; and Post, R.M. Cerebral atrophy in torture victims. [Letter] New England Journal of Medicine, 308(15):903-904, 1983.
42. King, D.J.; Burke, M.; and Lucas, R.A. Antipsychotic drug-induced dysphoria. British Journal of Psychiatry, 167:480-482, 1995.
43. Kocsis, J.H.; Frances, A.; Kaiman, T.P.; and Shear, M.K. The effect of psychobiological research on treatment outcome: A controlled study. Archives of General Psychiatry, 38:511-515, 1981.
44. Kreisman, D.; Blumenthal, R.; Borenstein, M.; Woerner, M.; Kane J.M.; Rifkin, A.; and Reardon, G. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: The family's view. Psychiatry, 51:3-13, 1988.
45. Ladd, C.O.; Owens, M.J.; and Nemeroff, C.B. Persistent changes in corticotrophin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology, 137(4): 1212-1219, 1996.
46. Leff, J.; Tress, K.; and Edwards, B. The clinical course of depressive symptoms in schizophrenia. Schizophrenia Research, 1(1):25-30, 1988.
47. Lerner, P.; Nosé, P.; Gordon, E.K.; and Lovenberg, W. Haloperidol: Effect of long-term treatment on rat striatal dopamine synthesis and turnover. Science, 197(4299): 181-183, 1977.
48. Loebel, A.D.; Lieberman, J.A.; Alvir, J.M.J.; Mayerhoff, D.I.; Geisler, S.H.; and Szymanski, S.R. Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry, 149:1183-1188, 1992.
49. Macklin, R. "Due" and "undue" inducements: On paying money to research subjects. IRB, 31:1-2, 1981.
50. Mandel, M.R.; Severe, J.B.; Schooler, M.R.; Gelenberg, A.J.; and Mieske, M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Archives of General Psychiatry, 39:197-203, 1982.
51. Matthews, S.M.; Roper, M.T.; Mosher, L.R.; and Menn, A.Z. A non-neuroleptic treatment for schizophrenia: Analysis of the two-year post-discharge risk of relapse. Schizophrenia Bulletin, 5(2):322-333, 1979.
52. May, P.R.A.; Tuma, A.H.; and Dixon, W.J. Schizophrenia: A follow-up study of results of five forms of treatment. Archives of General Psychiatry, 38:776-784, 1981.
53. McCrae, R.R. Are stress questionnaires stressful? IRB, 4:1-2, 1982.
54. McEwen, B.S.; Gould, E.A.; and Sakai, R.R. The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. British Journal of Psychiatry, 160(Suppl. 15): 18-24, 1992.
55. McGlashan, T.H. A selective review of recent North American long-term followup studies of schizophrenia. Schizophrenia Bulletin, 14(4):515-542, 1988.
56. McGlashan, T.H., and Carpenter, W.T., Jr. An investigation of the postpsychotic depressive syndrome. American Journal of Psychiatry, 133:14-19, 1976a.
57. McGlashan, T.H., and Carpenter, W.T., Jr. Postpsychotic depression in schizophrenia. Archives of General Psychiatry, 33:231-239, 1976b.
58. McWalter, H.S.; Mercer, R.; Sutherland, M.; and Watt, A. Outcomes of treatment of schizophrenia in a north-east Scottish mental hospital. American Journal of Psychiatry, 118:529-533, 1961.
59. Meshul, C.K., and Casey, D.E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Research, 489:338-346, 1989.
60. Moghaddam, B.; Bolinao, M.L.; Stein-Behrens, B.; and Sapolsky, R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Research, 655(1):251-254, 1994.
61. Mosher, L.R., and Menn, A.Z. Community residential treatment for schizophrenia: Two-year follow-up. Hospital and Community Psychiatry, 29:715-723, 1978.
62. Murakami, K. Changes in clinical course and symptomatology of schizophrenia following introduction of pharmacotherapy. [In Japanese] Psychiatrie et Neurologia Japonica, 73:635-649, 1971.
63. Ødegård, O. Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of psychotropic drugs. American Journal of Psychiatry, 120:772-778, 1964.
64. Peterson, D.B., and Olson, G.W. First admitted schizophrenics in drug era. Archives of General Psychiatry, 11:137-144, 1964.
65. Pietzcker, A.; Gaebel, W.; Köpeke, W.; Linden, M.; Müller, P.; Müller-Spahn, F.; and Tegeler, J. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2 year results of a German multicenter study. Journal of Psychiatry Research, 27(4):321-339, 1993.
66. Pritchard, D.M. Prognosis of schizophrenia before and after pharmacotherapy: I. Short term outcome. British Journal of Psychiatry, 113:1345-1352, 1967a.
67. Pritchard, D.M. Prognosis of schizophrenia before and after pharmacotherapy: II. Three-year follow-up. British Journal of Psychiatry, 113:1353-1359, 1967b.
68. Roberts, R.C.; Gaither, L.A.; Gao, X.M.; Kashyap, S.M.; and Tamminga, C.A. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse, 20:234-243, 1995.
69. Sapolsky, R.M. Potential behavioral modification of glucocorticoid damage to the hippocampus. Behavioral Brain Research, 57(2): 175-182, 1993.
70. Sapolsky, R.M. The physiological relevance of glucocorticoid endangerment of the hippocampus. Annals of the New York Academy of Sciences, 746:294-304, 1994.
71. Schooler, N.R. Maintenance medication for schizophrenia: Strategies for dose reduction. Schizophrenia Bulletin, 17(2):311-324, 1991.
72. Schooler, N.R.; Keith, S.J.; Severe, J.B.; and Matthews, S.M. Treatment strategies in schizophrenia: Effects of dosage reduction and family management on outcome. [Abstract] Schizophrenia Research, 9:260, 1993.
73. Shanfield, S.; Tucker, G.J.; Harrow, M.; and Detre, T. The schizophrenic patient and depressive symptomology. Journal of Nervous and Mental Disease, 151:203-210, 1970.
74. Shimazono, Y. Comment and discussion. In: Mitsuda, H., and Fukada, T., eds. Biological Mechanisms of Schizophrenia and Schizophrenia-Like Psychosis. Tokyo, Japan: Igaku Shoin, 1973. pp. 126-128.
75. Stephens, J.H. Long-term prognosis and followup in schizophrenia. Schizophrenia Bulletin, 4(1):25-47, 1978.
76. Stephens, J.H., and Astrup, C. Prognosis in "process" and "nonprocess" schizophrenia. American Journal of Psychiatry, 119:945-953, 1963.
77. Stephens, J.H.; Astrup, C.; and Mangrum, J.C. Prognostic factors in recovered and deteriorated schizophrenics. American Journal of Psychiatry, 122:1116-1121, 1966.
78. Strauss, J.S., and Carpenter, W.T., Jr. The prediction of outcome in schizophrenia: I. Characteristics of outcome. Archives of General Psychiatry, 27:739-746, 1972.
79. Strauss, M.E. Relations of symptoms to cognitive deficits in schizophrenia. Schizophrenia Bulletin, 19(2):215-231, 1993.
80. Vaillant, G.E. An historical review of the remitting schizophrenias. Journal of Nervous and Mental Disease, 138:48-56, 1964a.
81. Vaillant, G.E. Prospective prediction of schizophrenic remission. Archives of General Psychiatry, 11:509-518, 1964b.
82. Van Putten, T., and Marder, S.R. Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry, 48(Suppl. 9):13-19, 1987.
83. Van Putten, T., and May, P.R.A. "Akinetic depression" in schizophrenia. Archives of General Psychiatry, 35:1101-1107, 1978a.
84. Van Putten, T., and May, P.R.A. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Archives of General Psychiatry, 35:477-480, 1978b.
85. Virgin, C.E., Jr.; Ha, T.P.; Packan, D.R.; Tombaugh, G.C.; Yang, S.H.; Horner, H.C.; and Sapolsky, R.M. Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: Implications for glucocorticoid neurotoxicity. Journal of Neurochemistry, 57(4):1422-1428, 1991.
86. Waddington, J.L.; Youssef, H.A.; and Kinsella, A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychological Medicine, 25:849-857, 1995.
87. Watt, D.C.; Katz, K.; and Shepherd, M. The natural history of schizophrenia: A 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychological Medicine, 13:663-670, 1983.
88. Weiden, P.J., and Olfson, M. Cost of relapse in schizophrenia. Schizophrenia Bulletin. 21(3):419-429, 1995.
89. Willwerth, J. Tinkering with madness. Time, August 30, 1993. pp. 40-22.
90. Wisniewski, H.M.; Constantinidis, J.; Wegiel, J.; Bobinski, M.; and Tarnawski, M. Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics. Alzheimer Disease and Associated Disorders, 8(4):211-227, 1994.
91. Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17(3): 325-351, 1991.
92. Wyatt, R.J. Antipsychotic medication and the long-term course of schizophrenia: Therapeutic and theoretical implications. In: Shriqui, C., and Nasrallah, H., eds. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press, 1995a. pp. 385-410.
93. Wyatt, R.J. Risks of withdrawing antipsychotic medications. Archives of General Psychiatry, 52:205-208, 1995b.